Affinity: Patient Research
Research type
Research Study
Full title
Affinity: Patient Research for Usability and Handling
IRAS ID
288598
Contact name
Madeline Lok
Contact email
Sponsor organisation
Entia Ltd
Clinicaltrials.gov Identifier
n/a, n.a
Duration of Study in the UK
1 years, 6 months, 2 days
Research summary
This study, 'Affinity: Patient Research', is sponsored and funded by Entia Ltd. It is a co-design study between the investigator team, patients and where applicable, their carers.
Entia are seeking to develop the world's first home-based monitoring service to optimise the delivery of systemic therapy to cancer patients. As part of this service, a medical device will be co-designed, capable of performing a blood count from a finger prick sample of blood.
Entia are responsible for the study design, conduct and analysis of the research. The co-design model allows patients and their carers to be partners in the design process of the home monitoring system and provide vital insights and feedback.
Patients aged over 18+ who live in the UK and are currently undergoing systemic treatment for cancer therapy, or have done so in the last 12 months, will be eligible to take part.
Interested participants will be invited to take part in 60-90 minute workshops/interviews, either in person, or remotely from their own home.
During these workshops, they will be asked to provide feedback on a home monitoring system including a prototype device and cuvettes. Workshops will use creative ways to encourage a broad and unbiased way of thinking. Activities will include brainstorming exercises, problem-solving using prototypes, reviewing, testing and validating design proposals, assessing usability of and interaction with prototype designs along with test disposables. At some workshops, participants will be asked if they would be happy to take a finger prick sample, if they have consented to do so. This is completely optional.
REC name
London - Stanmore Research Ethics Committee
REC reference
20/LO/1091
Date of REC Opinion
18 Nov 2020
REC opinion
Further Information Favourable Opinion